



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

Approved for use through 07/31/2006. GMB-0057-0057
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			
<i>Complete if Known</i>			
Substitute for form 1449/PTO		Application Number	09/674,794
		Filing Date	August 21, 2001
		First Named Inventor	Melvyn Little
		Art Unit	1642
		Examiner Name	Unknown
Sheet	1	of	1
Attorney Docket Number			31304-756.831

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature	P. b. (P.M.)	Date Considered	9/9/15
--------------------	--------------	-----------------	--------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **1**Applicant's unique citation designation number (optional). **2**See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. **3**Enter Office that issued the document, by the two-letter code (WIPO Standard ST .3). **4**For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. **5**Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. **6**Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO.	APPLICATION NO.
		8484-089-999	09/674,794
		APPLICANT	
		Little et al.	
FILING DATE		GROUP	
November 3, 2000		To be assigned	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
------------------	--	-----------------	------	------	-------	----------	----------------------------

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES
							NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

PKT	AA	Gruber et al., 1994, "Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli", Journal of Immunology 10:5368-5374.
	AB	Mack et al., 1995, "A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity", Proceedings of the National Academy of Sciences of the United States of America 92:7021-7025.
	AC	Kurucz et al., 1995, "Retargeting f CTL by an efficiently refolded bispecific single-chain Fv dimer produced in bacteria", Journal of Immunology 154:4576-4582.
	AD	De Jonge et al., 1995, "Production and characterization of bispecific single-chain antibody fragments", Molecular Immunology 32:1405-1412.
	AE	Coloma et al., "Design and production of novel tetravalent bispecific antibodies", Nature Biotechnology 15:159-163.
	AF	Kipriyanov et al., 1999, "Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics", Journal of Molecular Biology 293:41-56.
	AG	Kipriyanov et al., 1996, J-Immunol. Meth. 196:51-62.
	AH	Kipriyanov et al., 1997, Protein Eng. 10:445-453.

EXAMINER	P. O. M. P.	DATE CONSIDERED	9/9/5
----------	-------------	-----------------	-------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.